1
|
Kubota K, Seki T, Miyake K, Okada M, Nishio K, Ohe K. Providing Practical Knowledge and Skills to Handle Real-World Data? Lessons Learned from Med RWD Program. Stud Health Technol Inform 2024; 310:1540-1541. [PMID: 38269735 DOI: 10.3233/shti231283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Abstract
Both lectures and hands-on education are essential for the development of human resources that can use real-world data (RWD). The University of Tokyo has launched a new hybrid-style RWD educational program entitled "Medical Real World Data Utilization Human Resource Development Project" from FY2019 onwards. We present an overview of the overall picture of the project, including the development process of the educational program and the challenges associated with it.
Collapse
|
2
|
Garon EB, Reck M, Nishio K, Heymach JV, Nishio M, Novello S, Paz-Ares L, Popat S, Aix SP, Graham H, Butts BD, Visseren-Grul C, Nakagawa K. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open 2023; 8:101580. [PMID: 37390764 PMCID: PMC10485403 DOI: 10.1016/j.esmoop.2023.101580] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 04/12/2023] [Accepted: 05/08/2023] [Indexed: 07/02/2023] Open
Abstract
BACKGROUND Ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) over placebo + ERL (PBO + ERL) in the phase III RELAY study of patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small-cell lung cancer (EGFR+ mNSCLC; NCT02411448). Next-generation sequencing (NGS) was used to identify clinically relevant alterations in circulating tumor DNA (ctDNA) and explore their impact on treatment outcomes. PATIENTS AND METHODS Eligible patients with EGFR+ mNSCLC were randomized 1 : 1 to ERL (150 mg/day) plus RAM (10 mg/kg)/PBO every 2 weeks. Liquid biopsies were to be prospectively collected at baseline, cycle 4 (C4), and postdiscontinuation follow-up. EGFR and co-occurring/treatment-emergent (TE) genomic alterations in ctDNA were analyzed using Guardant360 NGS platform. RESULTS In those with valid baseline samples, detectable activating EGFR alterations in ctDNA (aEGFR+) were associated with shorter PFS [aEGFR+: 12.7 months (n = 255) versus aEGFR-: 22.0 months (n = 131); hazard ratio (HR) = 1.87, 95% confidence interval (CI) 1.42-2.51]. Irrespective of detectable/undetectable baseline aEGFR, RAM + ERL was associated with longer PFS versus PBO + ERL [aEGFR+: median PFS (mPFS) = 15.2 versus 11.1 months, HR = 0.63, 95% CI 0.46-0.85; aEGFR-: mPFS = 22.1 versus 19.2 months, HR = 0.80, 95% CI 0.49-1.30]. Baseline alterations co-occurring with aEGFR were identified in 69 genes, most commonly TP53 (43%), EGFR (other than aEGFR; 25%), and PIK3CA (10%). PFS was longer in RAM + ERL, irrespective of baseline co-occurring alterations. Clearance of baseline aEGFR by C4 was associated with longer PFS (mPFS = 14.1 versus 7.0 months, HR = 0.481, 95% CI 0.33-0.71). RAM + ERL improved PFS outcomes, irrespective of aEGFR mutation clearance. TE gene alterations were most commonly in EGFR [T790M (29%), other (19%)] and TP53 (16%). CONCLUSIONS Baseline aEGFR alterations in ctDNA were associated with shorter mPFS. RAM + ERL was associated with improved PFS outcomes, irrespective of detectable/undetectable aEGFR, co-occurring baseline alterations, or aEGFR+ clearance by C4. aEGFR+ clearance by C4 was associated with improved PFS outcomes. Monitoring co-occurring alterations and aEGFR+ clearance may provide insights into mechanisms of EGFR tyrosine kinase inhibitor resistance and the patients who may benefit from intensified treatment schedules.
Collapse
Affiliation(s)
- E B Garon
- David Geffen School of Medicine at University of California Los Angeles/TRIO-US Network, Los Angeles, USA.
| | - M Reck
- LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany
| | - K Nishio
- Department of Medical Oncology, Kindai University, Osaka, Japan
| | - J V Heymach
- Department of Thoracic/Head & Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, USA; Department of Cancer Biology, University of Texas, MD Anderson Cancer Center, Houston, USA
| | - M Nishio
- Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Novello
- Department of Oncology, AOU San Luigi, University of Turin, Turin, Italy
| | - L Paz-Ares
- Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain
| | - S Popat
- Royal Marsden NHS Trust, London, UK
| | - S Ponce Aix
- Hospital Universitario 12 de Octubre, Madrid, Spain
| | - H Graham
- Eli Lilly and Company, Indianapolis, USA
| | - B D Butts
- Eli Lilly and Company, Indianapolis, USA
| | | | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
| |
Collapse
|
3
|
Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 2021; 33:216-226. [PMID: 34843940 DOI: 10.1016/j.annonc.2021.11.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 10/31/2021] [Accepted: 11/21/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Cancer of unknown primary (CUP) has a poor prognosis. Given the recent approval of immune checkpoint inhibitors for several cancer types, we carried out a multicenter phase II study to assess the efficacy of nivolumab for patients with CUP. PATIENTS AND METHODS Patients with CUP who were previously treated with at least one line of systemic chemotherapy constituted the principal study population. Previously untreated patients with CUP were also enrolled for exploratory analysis. Nivolumab (240 mg/body) was administered every 2 weeks for up to 52 cycles. The primary endpoint was objective response rate in previously treated patients as determined by blinded independent central review according to RECIST version 1.1. RESULTS Fifty-six patients with CUP were enrolled in the trial. For the 45 previously treated patients, objective response rate was 22.2% [95% confidence interval (CI), 11.2% to 37.1%], with a median progression-free survival and overall survival of 4.0 months (95% CI, 1.9-5.8 months) and 15.9 months (95% CI, 8.4-21.5 months), respectively. Similar clinical benefits were also observed in the 11 previously untreated patients. Better clinical efficacy of nivolumab was apparent for tumors with a higher programmed death-ligand 1 expression level, for those with a higher tumor mutation burden, and for microsatellite instability-high tumors. In contrast, no differences in efficacy were apparent between tumor subgroups based on estimated tissue of origin. Adverse events were consistent with the known safety profile of nivolumab. No treatment-related death was observed. CONCLUSIONS Our results demonstrate a clinical benefit of nivolumab for patients with CUP, suggesting that nivolumab is a potential additional therapeutic option for CUP.
Collapse
Affiliation(s)
- J Tanizaki
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - K Yonemori
- Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - K Akiyoshi
- Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan
| | - H Minami
- Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
| | - H Ueda
- Respiratory Medicine and Medical Oncology, Wakayama Medical University, Wakayama, Japan
| | - Y Takiguchi
- Department of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Miura
- Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan
| | - Y Segawa
- Department of Medical Oncology, International Medical Center, Saitama Medical University, Hidaka, Japan
| | - S Takahashi
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan
| | - Y Iwamoto
- Department of Medical Oncology, Hiroshima City Hospital Organization, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Y Kidera
- Clinical Research Center, Kindai University Hospital, Osakasayama, Japan
| | - K Fukuoka
- Clinical Research Center, Kindai University Hospital, Osakasayama, Japan
| | - A Ito
- Department ofPathology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - Y Chiba
- Clinical Research Center, Kindai University Hospital, Osakasayama, Japan
| | - K Sakai
- Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - K Nishio
- Department of Genome Biology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - H Hayashi
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan.
| |
Collapse
|
4
|
Nishio K, Udagawa Y. Formation of Nanoporous Gold Film on Ti by Anodization in Oxalic Acid. CHEM LETT 2021. [DOI: 10.1246/cl.210351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Kazuyuki Nishio
- Department of Applied Chemistry, School of Engineering, Tokyo University of Technology, 1404-1 Katakura, Hachioji, Tokyo 192-0982, Japan
| | - Yuta Udagawa
- Department of Applied Chemistry, School of Engineering, Tokyo University of Technology, 1404-1 Katakura, Hachioji, Tokyo 192-0982, Japan
| |
Collapse
|
5
|
Takahashi T, Nishio M, Yatabe Y, Nishino K, Yoshiki Y, Shiraiwa N, Emir B, Iadeluca L, Nishio K. P59.11 Real-World Data of NGS Diagnostic Biomarker Testing for Lung Cancer Patients in Japan. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Takahashi N, Izawa N, Nishio K, Masuishi T, Shoji H, Yamamoto Y, Matsumoto T, Sugiyama K, Kajiwara T, Kawakami K, Aomatsu N, Kawakami H, Esaki T, Narita Y, Hara H, Horie Y, Boku N, Miura K, Moriwaki T, Shimokawa M, Nakajima T, Muro K. O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Yatabe Y, Yoshiki Y, Matsumura K, Togo K, Kikkawa H, Masters E, Iadeluca L, Becnel L, Emir B, Wiltshire R, Nishio K. MA08.08 Implementation of Diagnostic Biomarker Testing in Lung Cancer: Real-World Data in Japan. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Hayashi H, Yonesaka K, Sugawara S, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Sakai K, Chiba Y, Nishio K, Yamamoto N, Nakagawa K. FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Pérez Sánchez R, Jurado B, Méot V, Roig O, Dupuis M, Bouland O, Denis-Petit D, Marini P, Mathieu L, Tsekhanovich I, Aïche M, Audouin L, Cannes C, Czajkowski S, Delpech S, Görgen A, Guttormsen M, Henriques A, Kessedjian G, Nishio K, Ramos D, Siem S, Zeiser F. Simultaneous Determination of Neutron-Induced Fission and Radiative Capture Cross Sections from Decay Probabilities Obtained with a Surrogate Reaction. Phys Rev Lett 2020; 125:122502. [PMID: 33016727 DOI: 10.1103/physrevlett.125.122502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Revised: 04/18/2020] [Accepted: 08/26/2020] [Indexed: 06/11/2023]
Abstract
Reliable neutron-induced-reaction cross sections of unstable nuclei are essential for nuclear astrophysics and applications but their direct measurement is often impossible. The surrogate-reaction method is one of the most promising alternatives to access these cross sections. In this work, we successfully applied the surrogate-reaction method to infer for the first time both the neutron-induced fission and radiative capture cross sections of ^{239}Pu in a consistent manner from a single measurement. This was achieved by combining simultaneously measured fission and γ-emission probabilities for the ^{240}Pu(^{4}He,^{4}He^{'}) surrogate reaction with a calculation of the angular-momentum and parity distributions populated in this reaction. While other experiments measure the probabilities for some selected γ-ray transitions, we measure the γ-emission probability. This enlarges the applicability of the surrogate-reaction method.
Collapse
Affiliation(s)
- R Pérez Sánchez
- CENBG, CNRS/IN2P3-Université de Bordeaux, Chemin du Solarium, B.P. 120, F-33175 Gradignan, France
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - B Jurado
- CENBG, CNRS/IN2P3-Université de Bordeaux, Chemin du Solarium, B.P. 120, F-33175 Gradignan, France
| | - V Méot
- CEA, DAM, DIF, F-91297 Arpajon, France
- Université Paris-Saclay, CEA, Laboratoire Matière sous Conditions Extrêmes, 91680 Bruyères-Le-Châtel, France
| | - O Roig
- CEA, DAM, DIF, F-91297 Arpajon, France
- Université Paris-Saclay, CEA, Laboratoire Matière sous Conditions Extrêmes, 91680 Bruyères-Le-Châtel, France
| | - M Dupuis
- CEA, DAM, DIF, F-91297 Arpajon, France
- Université Paris-Saclay, CEA, Laboratoire Matière sous Conditions Extrêmes, 91680 Bruyères-Le-Châtel, France
| | - O Bouland
- CEA-Cadarache, DEN/DER/SPRC/LEPh, F-13108 Saint Paul lez Durance, France
| | - D Denis-Petit
- CENBG, CNRS/IN2P3-Université de Bordeaux, Chemin du Solarium, B.P. 120, F-33175 Gradignan, France
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - P Marini
- CEA, DAM, DIF, F-91297 Arpajon, France
| | - L Mathieu
- CENBG, CNRS/IN2P3-Université de Bordeaux, Chemin du Solarium, B.P. 120, F-33175 Gradignan, France
| | - I Tsekhanovich
- CENBG, CNRS/IN2P3-Université de Bordeaux, Chemin du Solarium, B.P. 120, F-33175 Gradignan, France
| | - M Aïche
- CENBG, CNRS/IN2P3-Université de Bordeaux, Chemin du Solarium, B.P. 120, F-33175 Gradignan, France
| | - L Audouin
- Université Paris-Saclay, CNRS/IN2P3, IJC Lab, 91405 Orsay, France
| | - C Cannes
- Université Paris-Saclay, CNRS/IN2P3, IJC Lab, 91405 Orsay, France
| | - S Czajkowski
- CENBG, CNRS/IN2P3-Université de Bordeaux, Chemin du Solarium, B.P. 120, F-33175 Gradignan, France
| | - S Delpech
- Université Paris-Saclay, CNRS/IN2P3, IJC Lab, 91405 Orsay, France
| | - A Görgen
- Department of Physics, University of Oslo, 0316 Oslo, Norway
| | - M Guttormsen
- Department of Physics, University of Oslo, 0316 Oslo, Norway
| | - A Henriques
- CENBG, CNRS/IN2P3-Université de Bordeaux, Chemin du Solarium, B.P. 120, F-33175 Gradignan, France
| | - G Kessedjian
- Université Grenoble-Alpes, Grenoble INP, CNRS, LPSC-IN2P3, 38000 Grenoble, France
| | - K Nishio
- JAEA, Tokai, Ibaraki 319-1195, Japan
| | - D Ramos
- Université Paris-Saclay, CNRS/IN2P3, IJC Lab, 91405 Orsay, France
| | - S Siem
- Department of Physics, University of Oslo, 0316 Oslo, Norway
| | - F Zeiser
- Department of Physics, University of Oslo, 0316 Oslo, Norway
| |
Collapse
|
10
|
Kobayashi M, Yoshino O, Nakashima A, Ito M, Nishio K, Ono Y, Kusabiraki T, Kunitomi C, Takahashi N, Harada M, Hattori K, Orisaka M, Osuga Y, Saito S. Inhibition of autophagy in theca cells induces CYP17A1 and PAI-1 expression via ROS/p38 and JNK signalling during the development of polycystic ovary syndrome. Mol Cell Endocrinol 2020; 508:110792. [PMID: 32199904 DOI: 10.1016/j.mce.2020.110792] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 03/12/2020] [Accepted: 03/12/2020] [Indexed: 12/15/2022]
Abstract
Polycystic ovary syndrome (PCOS) is a clinical syndrome characterized by hyperandrogenism, oligo/anovulation, and polycystic ovary. Autophagy is an intracellular system that degrades cytosolic proteins and organelles. The relationship between autophagy and PCOS has not been clarified. We found that p62 and ubiquitin were significantly increased in theca cells of women with PCOS using immunohistochemistry. Autophagy inhibition by palmitic acid and chloroquine in bovine theca cells increased p62 and ubiquitin and induced the expression of cytochrome P450 17A1 (CYP17A1) and plasminogen activator inhibitor-1 (PAI-1) mRNA. Furthermore, palmitic acid and chloroquine exposure significantly increased reactive oxygen species (ROS) and activated p38 and c-Jun N-terminal kinase (JNK). Inhibition of p38 and JNK significantly reduced CYP17A1 and PAI-1 mRNA expression. We showed that inhibition of autophagy in theca cells may have contributed to the pathogenesis of PCOS, based on CYP17A1 and PAI-1 mRNA expression via the ROS/p38 and JNK signalling pathways.
Collapse
Affiliation(s)
- Mutsumi Kobayashi
- Department of Obstetrics and Gynaecology, University of Toyama, Toyama, 930-0194, Japan
| | - Osamu Yoshino
- Department of Obstetrics and Gynaecology, Kitasato University School of Medicine, Sagamihara, Kanagawa, 252-0375, Japan
| | - Akitoshi Nakashima
- Department of Obstetrics and Gynaecology, University of Toyama, Toyama, 930-0194, Japan
| | - Masami Ito
- Department of Obstetrics and Gynaecology, University of Toyama, Toyama, 930-0194, Japan
| | - Kazuyuki Nishio
- Division of Drug and Structural Research, Life Science Research Centre, University of Toyama, Toyama, 930-0194, Japan
| | - Yosuke Ono
- Department of Obstetrics and Gynaecology, University of Toyama, Toyama, 930-0194, Japan; Department of Obstetrics and Gynecology, Teine Keijinkai Hospital Sapporo, Hokkai-do, 006-8555, Japan
| | - Tae Kusabiraki
- Department of Obstetrics and Gynaecology, University of Toyama, Toyama, 930-0194, Japan
| | - Chisato Kunitomi
- Department of Obstetrics and Gynaecology, Faculty of Medicine, The University of Tokyo, Bunkyo, Tokyo, 113-8655, Japan
| | - Nozomi Takahashi
- Department of Obstetrics and Gynaecology, Faculty of Medicine, The University of Tokyo, Bunkyo, Tokyo, 113-8655, Japan
| | - Miyuki Harada
- Department of Obstetrics and Gynaecology, Faculty of Medicine, The University of Tokyo, Bunkyo, Tokyo, 113-8655, Japan
| | - Katsushige Hattori
- Department of Obstetrics and Gynaecology, University of Fukui, Yoshida, Fukui, 286-8686, Japan
| | - Makoto Orisaka
- Department of Obstetrics and Gynaecology, University of Fukui, Yoshida, Fukui, 286-8686, Japan
| | - Yutaka Osuga
- Department of Obstetrics and Gynaecology, Faculty of Medicine, The University of Tokyo, Bunkyo, Tokyo, 113-8655, Japan
| | - Shigeru Saito
- Department of Obstetrics and Gynaecology, University of Toyama, Toyama, 930-0194, Japan.
| |
Collapse
|
11
|
Tanaka T, Morita K, Morimoto K, Kaji D, Haba H, Boll RA, Brewer NT, Van Cleve S, Dean DJ, Ishizawa S, Ito Y, Komori Y, Nishio K, Niwase T, Rasco BC, Roberto JB, Rykaczewski KP, Sakai H, Stracener DW, Hagino K. Study of Quasielastic Barrier Distributions as a Step towards the Synthesis of Superheavy Elements with Hot Fusion Reactions. Phys Rev Lett 2020; 124:052502. [PMID: 32083897 DOI: 10.1103/physrevlett.124.052502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2019] [Revised: 12/06/2019] [Accepted: 01/09/2020] [Indexed: 06/10/2023]
Abstract
The excitation functions for quasielastic scattering of ^{22}Ne+^{248}Cm, ^{26}Mg+^{248}Cm, and ^{48}Ca+^{238}U are measured using a gas-filled recoil ion separator. The quasielastic barrier distributions are extracted for these systems and are compared with coupled-channel calculations. The results indicate that the barrier distribution is affected dominantly by deformation of the actinide target nuclei, but also by vibrational or rotational excitations of the projectile nuclei, as well as neutron transfer processes before capture. From a comparison between the experimental barrier distributions and the evaporation residue cross sections for Sg (Z=106), Hs (108), Cn (112), and Lv (116), it is suggested that the hot fusion reactions take advantage of a compact collision, where the projectile approaches along the short axis of a prolately deformed nucleus. A new method is proposed to estimate the optimum incident energy to synthesize unknown superheavy nuclei using the barrier distribution.
Collapse
Affiliation(s)
- T Tanaka
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
- Department of Physics, Kyushu University, Fukuoka 819-0395, Japan
- Department of Nuclear Physics, Research School of Physics and Engineering, The Australian National University, Canberra, Australian Capital Territory 2601, Australia
| | - K Morita
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
- Department of Physics, Kyushu University, Fukuoka 819-0395, Japan
| | - K Morimoto
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
| | - D Kaji
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
| | - H Haba
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
| | - R A Boll
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - N T Brewer
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S Van Cleve
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - D J Dean
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S Ishizawa
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
- Graduate School of Science and Engineering, Yamagata University, Yamagata 990-8560, Japan
| | - Y Ito
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - Y Komori
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
| | - K Nishio
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T Niwase
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
- Department of Physics, Kyushu University, Fukuoka 819-0395, Japan
| | - B C Rasco
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J B Roberto
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - K P Rykaczewski
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - H Sakai
- RIKEN Nishina Center for Accelerator-Based Science, Saitama 351-0198, Japan
| | - D W Stracener
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - K Hagino
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
- Research Center for Electron Photon Science, Tohoku University, Sendai 982-0826, Japan
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| |
Collapse
|
12
|
|
13
|
Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor. Ann Oncol 2019; 29:2145-2147. [PMID: 30099497 DOI: 10.1093/annonc/mdy312] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- K Kunimasa
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan.
| | - H Nakamura
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka City, Japan
| | - K Sakai
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
| | - M Kimura
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - T Inoue
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - M Tamiya
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - K Nishino
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - T Kumagai
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| | - S Nakatsuka
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka City, Japan
| | - H Endo
- Department of Biochemistry, Osaka International Cancer Institute, Osaka City, Japan
| | - M Inoue
- Department of Biochemistry, Osaka International Cancer Institute, Osaka City, Japan; Department of Clinical Bio-resource Research and Development, Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Nishio
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
| | - F Imamura
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka City, Japan
| |
Collapse
|
14
|
Nishio K, Sakai K, Seto T, Nishio M, Reck M, Garon E, Visseren-Grul C, Hozak R, Wijayawardana S, Enatsu S, Nakagawa K. Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumour DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global phase III study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Takeda M, Sakai K, Hayashi H, Tanaka K, Haratani K, Takahama T, Kato R, Yonesaka K, Nishio K, Nakagawa K. P2.14-15 Impact of Coexisting Gene Mutations in EGFR-Mutated Non–Small Cell Lung Cancer Before Treatment on EGFR T790M Mutation Status After EGFR-TKIs. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
16
|
Louzguine-Luzgin DV, Miyama M, Nishio K, Tsarkov AA, Greer AL. Vitrification and nanocrystallization of pure liquid Ni studied using molecular-dynamics simulation. J Chem Phys 2019; 151:124502. [PMID: 31575179 DOI: 10.1063/1.5119307] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Structural variation, vitrification, and crystallization processes in liquid nickel are simulated on continuous cooling and isothermal holding using a classical molecular-dynamics computer simulation procedure with an embedded-atom method potential at constant pressure. Structural changes are monitored with direct structure observation in the simulation cells, as well as by pair distribution and radial distribution functions created using the atomic coordinates. A cluster analysis is also performed. The crystallization kinetics is analyzed under isothermal conditions by monitoring density and energy variation as a function of time. As a result, a time-temperature-transformation diagram can be constructed over a wide temperature range.
Collapse
Affiliation(s)
- D V Louzguine-Luzgin
- MathAM-OIL, National Institute of Advanced Industrial Science and Technology (AIST), Sendai 980-8577, Japan
| | - M Miyama
- Department of Applied Information Sciences, Graduate School of Information Sciences, Tohoku University, Sendai 980-8579, Japan
| | - K Nishio
- MathAM-OIL, National Institute of Advanced Industrial Science and Technology (AIST), Sendai 980-8577, Japan
| | - A A Tsarkov
- National University of Science and Technology "MISiS", Moscow 119049, Russia
| | - A L Greer
- WPI Advanced Institute for Materials Research, Tohoku University, Aoba-Ku, Sendai 980-8577, Japan
| |
Collapse
|
17
|
Affiliation(s)
- Kazuyuki Nishio
- Department of Applied Chemistry, School of Engineering, Tokyo University of Technology, 1404-1 Katakura, Hachioji, Tokyo 192-0982, Japan
| | - Rimpei Sasaki
- Department of Applied Chemistry, School of Engineering, Tokyo University of Technology, 1404-1 Katakura, Hachioji, Tokyo 192-0982, Japan
| |
Collapse
|
18
|
Nishio M, Nishio K, Suzukawa K, Omori Y, Enatsu S, Visseren-Grul C, Nakagawa K. P3.01-75 RELAY+, an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1635] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Hata A, Katakami N, Nishino K, Mori M, Yokoyama T, Kurata T, Tachihara M, Takase N, Daga H, Kijima T, Morita S, Sakai K, Nishio K, Satouchi M, Negoro S. Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Kito Y, Yamada T, Matsumoto T, Yasui H, Murata K, Makiyama A, Hara H, Baba E, Nishio K, Yoshimura K, Hironaka S, Muro K, Yamazaki K. Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Ishii H, Azuma K, Sakai K, Naito Y, Matsuo N, Tokito T, Yamada K, Hoshino T, Nishio K. P3.01-45 Multifactorial Gene Alterations in EGFR Bypass Pathway are Induced by Afatinib in T790M-Mutant NSCLC Resistant to Osmertinib. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. P2.13-18 A Multicenter Prospective Biomarker Study to Explore Mechanisms of Afatinib Resistance Based on Digita PCR and Next-Generation Sequencing. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
23
|
Mizukami T, Sakai K, Naruki S, Taniyama T, Horie Y, Izawa N, Tsuda T, Fujino T, Boku N, Yasuda H, Fukunaga T, Nakajima TE, Nishio K. Identification of a FGFR3-TACC3 fusion in esophageal cancer. Ann Oncol 2018; 28:437-438. [PMID: 27771611 DOI: 10.1093/annonc/mdw550] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Mizukami
- Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - K Sakai
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
| | - S Naruki
- Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
| | - T Taniyama
- Division of Gastroenterology and Hepatology, Department of Internal Medicine St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - Y Horie
- Department of Gastroenterological and General Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - N Izawa
- Department of Gastroenterological and General Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - T Tsuda
- Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - T Fujino
- Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - N Boku
- Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - H Yasuda
- Internal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - T Fukunaga
- Division of Radiology, Department of Pathophysiological and Therapeutic Science, Faculty of Medicine, Tottori University, Japan
| | - T Eguchi Nakajima
- Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
| | - K Nishio
- Department of Internal Medicine, Matsui Hospital, Tokyo, Japan
| |
Collapse
|
24
|
Tai Y, Obayashi K, Yoshimoto K, Nishio K, Saeki K. 0184 Effect Of Bathing On Objective Sleep Quality Among Elderly: A Longitudinal Analysis Of Repeated Measurements In The Heijo-kyo Cohort. Sleep 2018. [DOI: 10.1093/sleep/zsy061.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y Tai
- Department of Epidemiology, Nara Medical University School of Medicine, Kashihara city, JAPAN
| | - K Obayashi
- Department of Epidemiology, Nara Medical University School of Medicine, Kashihara city, JAPAN
| | - K Yoshimoto
- Department of General Medicine, Nara Medical University School of Medicine, Kashihara city, JAPAN
| | - K Nishio
- Department of General Medicine, Nara Medical University School of Medicine, Kashihara city, JAPAN
| | - K Saeki
- Department of Epidemiology, Nara Medical University School of Medicine, Kashihara city, JAPAN
| |
Collapse
|
25
|
Nishio K, Tanihara F, Nguyen TV, Kunihara T, Nii M, Hirata M, Takemoto T, Otoi T. Effects of voltage strength during electroporation on the development and quality of in vitro-produced porcine embryos. Reprod Domest Anim 2018; 53:313-318. [PMID: 29135047 DOI: 10.1111/rda.13106] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2017] [Accepted: 10/10/2017] [Indexed: 12/20/2022]
Abstract
This study was conducted to determine suitable conditions for an experimental method in which the CRISPR/Cas9 system is introduced into in vitro-produced porcine zygotes by electroporation. In the first experiment, when putative zygotes derived from in vitro fertilization (IVF) were electroporated by either unipolar or bipolar pulses, keeping the voltage, pulse duration and pulse number fixed at 30 V/mm, 1 msec and five repeats, respectively, the rate of blastocyst formation from zygotes electroporated by bipolar pulses decreased compared to zygotes electroporated by unipolar pulses. In the second experiment, the putative zygotes were electroporated by electroporation voltages ranging from 20 V/mm-40 V/mm with five 1-msec unipolar pulses. The rate of cleavage and blastocyst formation of zygotes electroporated at 40 V/mm was significantly lower (p < .05) than that of zygotes electroporated at less than 30 V/mm. Moreover, the apoptotic nuclei indices of blastocysts derived from zygotes electroporated by voltages greater than 30 V/mm significantly increased compared with those from zygotes electroporated by voltages less than 25 V/mm (p < .05). When zygotes were electroporated with Cas9 mRNA and single-guide RNA (sgRNA) targeting site in the FGF10 exon 3, the proportions of blastocysts with targeted genomic sequences were 7.7% (2/26) and 3.6% (1/28) in the embryos derived from zygotes electroporated at 25 V/mm and 30 V/mm, respectively. Our results indicate that electroporation at 25 V/mm may be an acceptable condition for introducing Cas9 mRNA and sgRNA into pig IVF zygotes under which the viability of the embryos is not significantly affected.
Collapse
Affiliation(s)
- K Nishio
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - F Tanihara
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - T-V Nguyen
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - T Kunihara
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - M Nii
- Tokushima Prefectural Livestock Research Institute, Tokushima, Japan
| | - M Hirata
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - T Takemoto
- Institute for Advanced Medical Sciences, Tokushima University, Tokushima, Japan
| | - T Otoi
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| |
Collapse
|
26
|
Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 2018; 28:1532-1539. [PMID: 28407039 DOI: 10.1093/annonc/mdx183] [Citation(s) in RCA: 223] [Impact Index Per Article: 37.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2017] [Indexed: 12/22/2022] Open
Abstract
Background The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is unknown. We retrospectively evaluated nivolumab efficacy and immune-related factors in such patients according to their status for the T790M resistance mutation of EGFR. Patients and methods We identified 25 patients with EGFR mutation-positive NSCLC who were treated with nivolumab after disease progression during EGFR-TKI treatment (cohort A). Programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocyte (TIL) density in tumor specimens obtained after acquisition of EGFR-TKI resistance were determined by immunohistochemistry. Whole-exome sequencing of tumor DNA was carried out to identify gene alterations. The relation of T790M status to PD-L1 expression or TIL density was also examined in an independent cohort of 60 patients (cohort B). Results In cohort A, median progression-free survival (PFS) was 2.1 and 1.3 months for T790M-negative and T790M-positive patients, respectively (P = 0.099; hazard ratio of 0.48 with a 95% confidence interval of 0.20-1.24). Median PFS was 2.1 and 1.3 months for patients with a PD-L1 expression level of ≥1% or <1%, respectively (P = 0.084; hazard ratio of 0.37, 95% confidence interval of 0.10-1.21). PFS tended to increase as the PD-L1 expression level increased with cutoff values of ≥10% and ≥50%. The proportion of tumors with a PD-L1 level of ≥10% or ≥50% was higher among T790M-negative patients than among T790M-positive patients of both cohorts A and B. Nivolumab responders had a significantly higher CD8+ TIL density and nonsynonymous mutation burden. Conclusion T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level, than are T790M-positive patients.
Collapse
Affiliation(s)
- K Haratani
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - H Hayashi
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - T Tanaka
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki
| | - H Kaneda
- Department of Medical Oncology, Kishiwada City Hospital, Kishiwada
| | - Y Togashi
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama.,Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa
| | - K Sakai
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - K Hayashi
- Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki
| | - S Tomida
- Department of Biobank, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama
| | - Y Chiba
- Clinical Research Center, Kindai University Hospital, Osaka-Sayama
| | - K Yonesaka
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - Y Nonagase
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - T Takahama
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - J Tanizaki
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - K Tanaka
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - T Yoshida
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - K Tanimura
- Department of Respiratory Medicine, Kishiwada City Hospital, Kishiwada
| | - M Takeda
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - H Yoshioka
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki
| | - T Ishida
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki
| | - T Mitsudomi
- Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
| | - K Nishio
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama
| |
Collapse
|
27
|
Matsuda S, Suzuki S, Morimoto K, Aono A, Nishio K, Asakura T, Sasaki Y, Namkoong H, Nishimura T, Ogata H, Hasegawa N, Kurashima A, Ishii M, Tatsumi K, Mitarai S, Goto H. Mycobacterium triplex pulmonary disease with acquired macrolide resistance in immunocompetent patients. Clin Microbiol Infect 2018; 24:671-672. [PMID: 29309938 DOI: 10.1016/j.cmi.2017.12.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 12/25/2017] [Accepted: 12/26/2017] [Indexed: 11/26/2022]
Affiliation(s)
- S Matsuda
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - S Suzuki
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - K Morimoto
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan; Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
| | - A Aono
- Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - K Nishio
- Department of Respiratory Medicine, Kawasaki Municipal Ida Hospital, Kanagawa, Japan
| | - T Asakura
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Y Sasaki
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - H Namkoong
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - T Nishimura
- Health Centre, Keio University, Tokyo, Japan
| | - H Ogata
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - N Hasegawa
- Centre for Infectious Diseases and Infection Control, Keio University School of Medicine, Tokyo, Japan
| | - A Kurashima
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - M Ishii
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
| | - K Tatsumi
- Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - S Mitarai
- Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan
| | - H Goto
- Respiratory Disease Centre, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| |
Collapse
|
28
|
Nguyen TV, Tanihara F, Hirata M, Hirano T, Nishio K, Kim Do LT, Nguyen TV, Nii M, Otoi T. Effects of Antifreeze Protein Supplementation on the Development of Porcine Morulae Stored at Hypothermic Temperatures. Cryo Letters 2018; 39:131-136. [PMID: 29734422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
BACKGROUND Short-term storage is valuable method to reuse manipulated embryos. OBJECTIVE The present study evaluated the effects of antifreeze protein (AFP) supplementation on the quality and development of in vitro-produced porcine morulae after short-term storage (24 h). MATERIALS AND METHODS The morulae were stored with various concentrations of AFP type III for 24 h at 5, 15 and 25C. RESULTS Supplementation of AFP type III (1.0 microgram per mL) improved the developmental competence of embryos stored at 25C. The proportions of DNA-fragmented nuclei in the blastocysts did not differ between the embryos stored at 25C and the control embryos without storage treatment. However, the developmental competence of embryos stored at hypothermic temperatures decreased relative to that of the control embryos. CONCLUSION Supplementation of AFP type III (1.0 microgram per mL) maintained the quality of embryos stored at 25C, but did not have beneficial effects on the development of embryos stored at hypothermic temperatures.
Collapse
Affiliation(s)
- T V Nguyen
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - F Tanihara
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - M Hirata
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - T Hirano
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - K Nishio
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan
| | - L T Kim Do
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan. Faculty of Veterinary Science, Vietnam National University of Agriculture, Vietnam
| | - T V Nguyen
- Faculty of Veterinary Science, Vietnam National University of Agriculture, Vietnam
| | - M Nii
- Tokushima Prefectural Livestock Research Institute, Tokushima, Japan
| | - T Otoi
- Faculty of Bioscience and Bioindustry, Tokushima University, Tokushima, Japan.
| |
Collapse
|
29
|
Abstract
In the last two decades, through technological, experimental and theoretical advances, the situation in experimental fission studies has changed dramatically. With the use of advanced production and detection techniques both much more detailed and precise information can now be obtained for the traditional regions of fission research and, crucially, new regions of nuclei have become routinely accessible for fission studies. This work first of all reviews the recent developments in experimental fission techniques, in particular the resurgence of transfer-induced fission reactions with light and heavy ions, the emerging use of inverse-kinematic approaches, both at Coulomb and relativistic energies, and of fission studies with radioactive beams. The emphasis on the fission-fragment mass and charge distributions will be made in this work, though some of the other fission observables, such as prompt neutron and γ-ray emission will also be reviewed. A particular attention will be given to the low-energy fission in the so far scarcely explored nuclei in the very neutron-deficient lead region. They recently became the focus for several complementary experimental studies, such as β-delayed fission with radioactive beams at ISOLDE(CERN), Coulex-induced fission of relativistic secondary beams at FRS(GSI), and several prompt fusion-fission studies. The synergy of these approaches allows a unique insight in the new region of asymmetric fission around [Formula: see text]Hg, recently discovered at ISOLDE. Recent extensive theoretical efforts in this region will also be outlined. The unprecedented high-quality data for fission fragments, completely identified in Z and A, by means of reactions in inverse kinematics at FRS(GSI) and VAMOS(GANIL) will be also reviewed. These experiments explored an extended range of mercury-to-californium elements, spanning from the neutron-deficient to neutron-rich nuclides, and covering both asymmetric, symmetric and transitional fission regions. Some aspects of heavy-ion induced fusion-fission and quasifission reactions will be also discussed, which reveal their dynamical features, such as the fission time scale. The crucial role of the multi-chance fission, probed by means of multinucleon-transfer induced fission reactions, will be highlighted. The review will conclude with the discussion of the new experimental fission facilities which are presently being brought into operation, along with promising 'next-generation' fission approaches, which might become available within the next decade.
Collapse
Affiliation(s)
- A N Andreyev
- Department of Physics, University of York, York, YO10 5DD, United Kingdom. Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | | | | |
Collapse
|
30
|
Hirose K, Nishio K, Tanaka S, Léguillon R, Makii H, Nishinaka I, Orlandi R, Tsukada K, Smallcombe J, Vermeulen MJ, Chiba S, Aritomo Y, Ohtsuki T, Nakano K, Araki S, Watanabe Y, Tatsuzawa R, Takaki N, Tamura N, Goto S, Tsekhanovich I, Andreyev AN. Role of Multichance Fission in the Description of Fission-Fragment Mass Distributions at High Energies. Phys Rev Lett 2017; 119:222501. [PMID: 29286806 DOI: 10.1103/physrevlett.119.222501] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2017] [Indexed: 06/07/2023]
Abstract
Fission-fragment mass distributions were measured for ^{237-240}U, ^{239-242}Np, and ^{241-244}Pu populated in the excitation-energy range from 10 to 60 MeV by multinucleon transfer channels in the reaction ^{18}O+^{238}U at the Japan Atomic Energy Agency tandem facility. Among them, the data for ^{240}U and ^{240,241,242}Np were observed for the first time. It was found that the mass distributions for all the studied nuclides maintain a double-humped shape up to the highest measured energy in contrast to expectations of predominantly symmetric fission due to the washing out of nuclear shell effects. From a comparison with the dynamical calculation based on the fluctuation-dissipation model, this behavior of the mass distributions was unambiguously attributed to the effect of multichance fission.
Collapse
Affiliation(s)
- K Hirose
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - K Nishio
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - S Tanaka
- Faculty of Science and Engineering, Kindai University, Higashi-Osaka 577-8502, Japan
| | - R Léguillon
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - H Makii
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - I Nishinaka
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - R Orlandi
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - K Tsukada
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - J Smallcombe
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - M J Vermeulen
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
| | - S Chiba
- Laboratory for Advanced Nuclear Energy, Institute for Innovative Research, Tokyo Institute of Technology, 2-12-1-N1-19, Ookayama, Meguro-ku, Tokyo 152-8550 Japan
| | - Y Aritomo
- Faculty of Science and Engineering, Kindai University, Higashi-Osaka 577-8502, Japan
| | - T Ohtsuki
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - K Nakano
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Fukuoka 816-8580, Japan
| | - S Araki
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Fukuoka 816-8580, Japan
| | - Y Watanabe
- Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, Fukuoka 816-8580, Japan
| | - R Tatsuzawa
- Graduate School of Engineering, Tokyo City University, Tokyo 158-8557, Japan
| | - N Takaki
- Graduate School of Engineering, Tokyo City University, Tokyo 158-8557, Japan
| | - N Tamura
- Graduate School of Science and Technology, Niigata University, Niigata 950-2181, Japan
| | - S Goto
- Graduate School of Science and Technology, Niigata University, Niigata 950-2181, Japan
| | - I Tsekhanovich
- University of Bordeaux, 351 Cours de la Libration, 33405 Talence Cedex, France
| | - A N Andreyev
- Advanced Science Research Center, Japan Atomic Energy Agency (JAEA), 2-4 Shirakata Shirane, Tokai, Ibaraki 319-1195 Japan
- Department of Physics, University of York, York YO10 5DD, United Kingdom
| |
Collapse
|
31
|
Yonesaka K, Kudoh K, Takamura S, Sakai H, Kato R, Haratani K, Takahama T, Tanaka K, Hayashi H, Kaneda H, Takeda M, Maenishi O, Yamato M, Miyazawa M, Nishio K, Nakagawa K. P2.07-021 A Checkpoint Molecule B7-H3 as a Novel Immune Therapy Target for Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
32
|
|
33
|
Tatemizo N, Imada S, Miura Y, Nishio K, Isshiki T. Crystallographic and electronic properties of AlCrN films that absorb visible light. AIP Adv 2017; 7:055306. [PMID: 28529820 PMCID: PMC5425299 DOI: 10.1063/1.4983491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 05/01/2017] [Indexed: 06/07/2023]
Abstract
We investigate the crystallographic and electronic properties of wurtzite Cr-doped AlN (AlCrN) films (Cr ≤12.0%) that absorb visible light. We confirmed that the films consist of wurtzite columnar single crystals that are densely packed, c-axis oriented, and exhibit a random rotation along the a-axis in plane by using transmission electron microscopy. The oxidation state of Cr was found to be 3+ using Cr K-edge X-ray absorption near edge structure, which implies that Cr can be a substitute for Al3+ in AlN. The first nearest neighbor distances estimated using Cr K-edge extended X-ray absorption fine structure (EXAFS) were found to be nearly isotropic for incident light with electric fields that are parallel and perpendicular to the plane. The results of ab initio lattice relaxation calculations for the model of wurtzite Al1-xCrxN supercell where Cr replaces Al support the EXAFS results. The calculations for the model showed that additional energy bands are formed in the band gap of AlN, in which the Fermi energy (EF ) is present. As expected from the calculation results, the electrical conductivity increases with increase in the Cr concentration, implying that the density of states at EF increases monotonically. From these results, we can conclude that AlCrN films are an intermediate band material with respect to their crystallographic and electric properties.
Collapse
Affiliation(s)
- N Tatemizo
- Faculty of Electrical Engineering and Electronics, Kyoto Institute of Technology, Kyoto 606-8585, Japan
| | - S Imada
- Faculty of Electrical Engineering and Electronics, Kyoto Institute of Technology, Kyoto 606-8585, Japan
| | - Y Miura
- Faculty of Electrical Engineering and Electronics, Kyoto Institute of Technology, Kyoto 606-8585, Japan
| | - K Nishio
- Faculty of Electrical Engineering and Electronics, Kyoto Institute of Technology, Kyoto 606-8585, Japan
| | - T Isshiki
- Faculty of Electrical Engineering and Electronics, Kyoto Institute of Technology, Kyoto 606-8585, Japan
| |
Collapse
|
34
|
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. Abstract P4-21-14: A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.
Citation Format: Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-14.
Collapse
Affiliation(s)
- T Takano
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - J Tsurutani
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - M Takahashi
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - T Yamanaka
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Sakai
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - Y Ito
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - J Fukuoka
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - H Kimura
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - H Kawabata
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Tamura
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Matsumoto
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Aogi
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Sato
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Nishio
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - K Nakagawa
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| | - T Saeki
- Toranomon Hospital, Tokyo, Japan; Kindai University, Osaka, Japan; NHO Hokkaido Cancer Center, Hokkaido, Japan; Yokohama City University, Kanagawa, Japan; Cancer Institute Hospital, Tokyo, Japan; Pathology Institute, Toyama, Japan; Kanazawa University, Ishikawa, Japan; National Cancer Center Hospital, Tokyo, Japan; Hyogo Cancer Center, Hyogo, Japan; Shikoku Cancer Center, Ehime, Japan; Tokyo-West Tokushukai Hospital, Tokyo, Japan; Saitama Medical University, Saitama, Japan
| |
Collapse
|
35
|
Tsurutani J, Sakai K, Takao T, Kimura H, Kawabata H, Tanaka K, Takahashi M, Ito Y, Takao S, Aogi K, Sato K, Tsuji Y, Yamanaka T, Nakanishi Y, Saeki T, Nishio K. Abstract P2-05-24: Prognostic value of circulating PIK3CA mutations revealed with digital PCR in patients with HER2-positive advanced breast cancer: Results of West Japan Oncology Group study 6110BTR. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- J Tsurutani
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Sakai
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Takao
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - H Kimura
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - H Kawabata
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Tanaka
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - M Takahashi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Ito
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - S Takao
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Aogi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Sato
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Tsuji
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Yamanaka
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Y Nakanishi
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - T Saeki
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - K Nishio
- Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan; Toranomon Hospital, Minato, Tokyo, Japan; Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan; NHO Hokkaido Cancer Center, Sapporo, Hokaido, Japan; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Kotoh, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan; Tokyo-West Tokushukai Hospital, Akishima, Tokyo, Japan; Tonan Hospital, Sapporo, Hokkaido, Japan; Yokohama City University, Yokohama, Kanagawa, Japan; Kyushu University, Fukuoka, Japan; Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| |
Collapse
|
36
|
Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations. Ann Oncol 2017; 28:136-141. [DOI: 10.1093/annonc/mdw531] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
37
|
Takeda M, Sakai K, Okamoto K, Hayashi H, Tanaka K, Shimizu T, Nishio K, Nakagawa K. Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity. Ann Oncol 2016; 27:748-50. [PMID: 26787234 DOI: 10.1093/annonc/mdw021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
| | - K Sakai
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
| | | | | | | | | | - K Nishio
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
| | | |
Collapse
|
38
|
Togashi Y, Nakamura Y, Tomida S, Hayashi H, de Velasco M, Sakai K, Fujita Y, Hamada S, Nishio K. 329P Afatinib activity against head-and-neck or esophageal squamous cell carcinoma: Significance of activating oncogenic HER4 mutations in head-and-neck squamous cell carcinoma. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv527.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Iwama E, Sakai K, Azuma K, Nosaki K, Harada D, Hotta K, Ohyanagi F, Kurata T, Akamatsu H, Goto K, Fukuhara T, Nakanishi Y, Nishio K, Okamoto I. 484PD A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv533.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Nagai H, Oiso N, Tomida S, Sakai K, Fujiwara S, Nakamachi Y, Kawano S, Kawada A, Nishio K, Nishigori C. Epidermolysis bullosa simplex with mottled pigmentation with noncicatricial alopecia: identification of a recurrent p.P25L mutation inKRT5in four affected family members. Br J Dermatol 2015; 174:633-5. [DOI: 10.1111/bjd.14083] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- H. Nagai
- Division of Dermatology; Department of Internal Medicine; Kobe University Graduate School of Medicine; 7-5-1 Kusunoki-cho, Chuo-ku Kobe 650-0017 Japan
| | - N. Oiso
- Department of Dermatology; Kinki University Faculty of Medicine; Osaka-Sayama Japan
| | - S. Tomida
- Department of Genome Biology; Kinki University Faculty of Medicine; Osaka-Sayama Japan
| | - K. Sakai
- Department of Genome Biology; Kinki University Faculty of Medicine; Osaka-Sayama Japan
| | - S. Fujiwara
- Division of Dermatology; Department of Internal Medicine; Kobe University Graduate School of Medicine; 7-5-1 Kusunoki-cho, Chuo-ku Kobe 650-0017 Japan
| | - Y. Nakamachi
- Department of Clinical Laboratory; Kobe University Hospital; Kobe Japan
| | - S. Kawano
- Division of Laboratory Medicine; Department of Internal Medicine; Kobe University Graduate School of Medicine; 7-5-1 Kusunoki-cho, Chuo-ku Kobe 650-0017 Japan
| | - A. Kawada
- Department of Dermatology; Kinki University Faculty of Medicine; Osaka-Sayama Japan
| | - K. Nishio
- Department of Genome Biology; Kinki University Faculty of Medicine; Osaka-Sayama Japan
| | - C. Nishigori
- Division of Dermatology; Department of Internal Medicine; Kobe University Graduate School of Medicine; 7-5-1 Kusunoki-cho, Chuo-ku Kobe 650-0017 Japan
| |
Collapse
|
41
|
Takeda M, Sakai K, Terashima M, Kaneda H, Hayashi H, Tanaka K, Okamoto K, Takahama T, Yoshida T, Iwasa T, Shimizu T, Nonagase Y, Kudo K, Tomida S, Mitsudomi T, Saigo K, Ito A, Nakagawa K, Nishio K. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann Oncol 2015; 26:2477-82. [PMID: 26420428 DOI: 10.1093/annonc/mdv475] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 09/18/2015] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The clinical implementation of genomic profiling for lung cancer with high-throughput, multiplex tests is warranted to allow prioritization of appropriate therapies for individual patients. We have now applied such testing to detect actionable mutations that may inform treatment recommendations in lung cancer. PATIENTS AND METHODS We prospectively applied amplicon sequencing panels that cover both mutational hotspots in 22 genes related to lung and colon tumorigenesis as well as 72 major variants of ALK, RET, ROS1, and NTRK1 fusion transcripts. We then determined the proportion of patients who received genotype-directed therapy and their overall survival (OS). RESULTS Tumor specimens from 110 patients with lung cancer recruited between July 2013 and March 2015 were analyzed. The most common genetic alterations were TP53 mutations in 42 patients, followed by EGFR mutations in 25, STK11 mutations in 12, and KRAS mutations in 10. Potentially actionable mutations were identified in 44 patients including 50% of those with adenocarcinoma and 14% of those with squamous cell carcinoma. The OS of patients with advanced or recurrent cancer who had an actionable mutation and received targeted therapy (median OS not achieved) was significantly longer than that of those with no mutation (18.1 months, P = 0.041) or of those with a mutation not so treated (6.1 months, P = 0.0027). CONCLUSIONS Multiplex genomic testing was performed on formalin-fixed, paraffin-embedded tumor specimens with a success rate of ≥95%. Such testing can assist physicians in matching patients with approved or experimental targeted treatments. CLINICAL TRIAL REGISTRATION The University Medical Hospital Information Network (UMIN) Clinical Trials Registry under the identifier UMIN000014782.
Collapse
Affiliation(s)
| | - K Sakai
- Department of Genome Biology
| | | | | | | | | | | | | | | | - T Iwasa
- Department of Medical Oncology
| | | | | | - K Kudo
- Department of Medical Oncology
| | | | - T Mitsudomi
- Division of Thoracic Surgery, Department of Surgery
| | - K Saigo
- Department of Neurology Department of Medical Genetics
| | - A Ito
- Department of Pathology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan
| | | | | |
Collapse
|
42
|
Tanaka Y, Aoyagi K, Minashi K, Komatsuzaki R, Komatsu M, Takahashi N, Oda I, Tachimori Y, Arao T, Nishio K, Kitano S, Muto M, Yamada Y, Sasaki H. 104 CDH2 negative esophageal squamous cell carcinoma with cytotoxic T-lymphocyte signatures is a good responder subtype to definitive chemoradiotherapy. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30004-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Togashi Y, Yoshioka Y, Chikugo T, Terashima M, Mizukami T, Hayashi H, Sakai K, Velasco MD, Tomida S, Fujita Y, Okuno K, Nishio K. 2169 Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinoma. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31089-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Fujita Y, Yamazaki K, Oba M, Muro K, Negoro Y, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Seki N, Sato M, Ebi M, Tamagawa H, Ueda S, Tamura T, Boku N, Hyodo I, Yamanaka T, Tsurutani J, Nishio K. 2152 Exploratory analysis of predictive biomarkers of oxaliplatin versus irinotecan in combination with bevacizumab for patients with metastatic colorectal cancer in WJOG4407G study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31073-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
45
|
Hayashi H, Togashi Y, Terashima M, Sakai K, Mizuuchi H, Kobayashi Y, Suda K, Nakagawa K, Nishio K, Mitsudomi T. 3016 Receptor tyrosine kinase mutations in non-small cell lung cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31660-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
46
|
Mizukami T, Togashi Y, Banno E, Terashima M, de Velasco M, Sakai K, Hayashi H, Fujita Y, Tomida S, Eguchi Nakajima T, Boku N, Ito A, Nakagawa K, Nishio K. 259 Fibroblast growth factor 9 gene amplification can induce resistance to anti-EGFR therapy in colorectal cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30145-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
47
|
Togashi Y, Mizuuchi H, Kobayashi Y, Hayashi H, Terashima M, Sakai K, Banno E, Mizukami T, Nakamura Y, de Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer. Ann Oncol 2015; 26:1800-1. [PMID: 26002608 DOI: 10.1093/annonc/mdv240] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Y Togashi
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - H Mizuuchi
- Department of Thoracic Surgery, Kinki University Faculty of Medicine, Osaka, Japan
| | - Y Kobayashi
- Department of Thoracic Surgery, Kinki University Faculty of Medicine, Osaka, Japan
| | - H Hayashi
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - M Terashima
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - K Sakai
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - E Banno
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - T Mizukami
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - Y Nakamura
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - M A de Velasco
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - Y Fujita
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - S Tomida
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| | - T Mitsudomi
- Department of Thoracic Surgery, Kinki University Faculty of Medicine, Osaka, Japan
| | - K Nishio
- Department of Genome Biology, Kinki University Faculty of Medicine, Osaka, Japan
| |
Collapse
|
48
|
Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne PA, Nakagawa K. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. Oncogene 2015; 35:878-86. [PMID: 25961915 DOI: 10.1038/onc.2015.142] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2014] [Revised: 03/17/2015] [Accepted: 03/23/2015] [Indexed: 11/09/2022]
Abstract
Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a monoclonal antibody against HER3 that has shown promising results in early-phase clinical trials, but an optimal target population for the drug has yet to be identified. In the present study, we examined whether heregulin, a HER3 ligand that is also overexpressed in a subset of NSCLC, can be used as a biomarker to predict the antitumorigenic efficacy of patritumab and whether the drug can overcome the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistance induced by heregulin. Patritumab sensitivity was associated with heregulin expression, which, when abolished, resulted in the loss of HER3 and AKT activation and growth arrest. Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. Sustained HER3-AKT activation was blocked by combining erlotinib with either anti-HER2 or anti-HER3 antibody. Notably, heregulin was upregulated in tissue samples from an NSCLC patient who had an activating EGFR mutation but was resistant to the TKI gefitinib. These results indicate that patritumab can overcome heregulin-dependent EGFR inhibitor resistance in NSCLC in vitro and in vivo and suggest that it can be used in combination with EGFR TKIs to treat a subset of heregulin-overexpressing NSCLC patients.
Collapse
Affiliation(s)
- K Yonesaka
- Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
| | - K Hirotani
- Daiichi-Sankyo Pharmaceutical Development, Tokyo, Japan
| | - H Kawakami
- Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
| | - M Takeda
- Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
| | - H Kaneda
- Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
| | - K Sakai
- Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan
| | - I Okamoto
- Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
| | - K Nishio
- Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan
| | - P A Jänne
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.,Department of Medicine, Brigham Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - K Nakagawa
- Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan
| |
Collapse
|
49
|
Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K. A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer. Br J Cancer 2015; 112:819-24. [PMID: 25654665 PMCID: PMC4453950 DOI: 10.1038/bjc.2015.10] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Revised: 12/12/2014] [Accepted: 12/21/2014] [Indexed: 02/07/2023] Open
Abstract
Background: We evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, recommended dose for phase II (P2RD), and preliminary anticancer activity of a combination eribulin and S-1 therapeutic in metastatic breast cancer patients pretreated with anthracycline and taxane. Method: Patients aged 20–74 years were recruited. In level 1, patients received S-1 (65 mg m−2) from day 1 to 14, and eribulin (1.1 mg m−2) on day 1 and 8 in a 21-day cycle. In level 2, eribulin was increased to 1.4 mg m−2. In level 3, S-1 was increased to 80 mg m−2. Results: Twelve patients were enrolled into three cohorts. Planned dose escalation was completed, with one case exhibiting dose-limiting toxicity (grade 3 hypokalaemia) at level 3, without reaching the MTD. The P2RD was determined to be level 2 (eribulin 1.4 mg m−2 and S-1 65 mg m−2). The most common grade 3 or 4 toxicity was neutropenia (83.3%), followed by febrile neutropenia (25.0%). Five of eleven patients (41.7%) with measurable disease had a partial response. Pharmacokinetics were characterised by dose-dependent elimination and nonlinear exposure. Conclusion: Dose level 3 was not tolerated owing to febrile neutropenia development. Thus, intermediate dose level 2 was recommended for further evaluation. Preliminary antitumour activity warrants further investigation in this setting.
Collapse
Affiliation(s)
- T Sakiyama
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - J Tsurutani
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - T Iwasa
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - H Kawakami
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - Y Nonagase
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - T Yoshida
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - K Tanaka
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - Y Fujisaka
- Clinical Research Center, Osaka Medical Collage Hospital, 2-7 Daigaku-cho, Takatsuki 569-8686, Japan
| | - T Kurata
- Department of Thoracic Oncology, Kansai Medical University Hirakata Hospital, 2-3-1 Shinmachi, Hirakata 573-1191, Japan
| | - Y Komoike
- Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - K Nishio
- Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| | - K Nakagawa
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan
| |
Collapse
|
50
|
Kimura M, Makio K, Hara K, Hiruma W, Fujita Y, Takata T, Nishio K, Ono N. A Supramolecular Substance, [2] Rotaxane, Induces Apoptosis in Human Molt-3 Acute Lymphoblastic Leukemia Cells. Drug Res (Stuttg) 2014; 65:614-6. [PMID: 25463596 DOI: 10.1055/s-0034-1395628] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The antitumor effects of a supramolecular substance, the [2] rotaxane (TRO-A0001), and its molecular mechanisms were investigated. TRO-A0001 suppressed the proliferation of cultured human Molt-3 acute lymphoblastic leukemia cells for 12-72 h in a dose-dependent manner. Based on flow cytometry, TRO-A0001 clearly induced apoptosis after 24 h. The mitochondrial membrane potential disappeared after treatment with 1.0 µM of TRO-A0001. Expression of the cleaved forms of capase-9 and caspase-3 was significantly increased in cells exposed to TRO-A0001, whereas the expression of XIAP, a type of inhibitor of apoptosis family, was decreased. These results suggest that [2] rotaxane TRO-A0001 may be a highly promising new antitumor medicine.
Collapse
Affiliation(s)
- M Kimura
- Medicinal-Informatics and Research Unit, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
| | - K Makio
- Medicinal-Informatics and Research Unit, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
| | - K Hara
- Medicinal-Informatics and Research Unit, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
| | - W Hiruma
- Medicinal-Informatics and Research Unit, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
| | - Y Fujita
- Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan
| | - T Takata
- Department of Organic and Polymeric Materials, Tokyo Institute of Technology, Tokyo, Japan
| | - K Nishio
- Department of Genome Biology, Kinki University School of Medicine, Osaka, Japan
| | - N Ono
- Medicinal-Informatics and Research Unit, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
| |
Collapse
|